Dr Hurwitz on the Feasibility of Utilizing CAR T-Cell Therapy in Solid Tumors
Michael Hurwitz, MD, PhD, associate professor, Internal Medicine (Medical Oncology), Yale School of Medicine, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.Source: OncLive
Dr. Michael Karellas on Yale Cancer Answers
In honor of Movember and Men's Health, urologic oncologist Dr. Michael Karellas discusses the importance of yearly check-ups for men and screening that is available for certain urologic cancers. Listen live on Connecticut Public Radio or download our podcast from iTunes.
Practical Considerations for the Treatment of Patients With Metastatic Castration-Sensitive Prostate Cancer
Yale Urology's Joseph Renzulli, MD, spoke to Urology Times about the treatment of patients with advanced prostate cancer. Takeaways include: ▫ doublet/combination therapy can make both survival AND quality of life improvements ▫ clinicians should consider combination approaches as standard-of-care for metastatic castration-sensitive prostate cancer ▫ timing is everything; don't necessarily wait, don't necessarily stagger combination therapies ▫ chemotherapy with ADT is NOT a must ▫ individualized treatment is key Read the full Q&A...Source: Urology Times
"Encouraging Results" in Patients With AR Ligand Binding Domain Mutated mCRPC
Daniel Petrylak, MD, discusses radiographic progression-free survival (rPFS) in patients with AR ligand-binding domain mutations in the phase 1/2 study of bavdegalutamide, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer (mCRPC) at the recent 2023 ESMO annual meeting.Source: Uro/GU Onc Today
Rare Case of Late-recurring Merkel Cell Carcinoma
Merkel cell carcinoma is a rare, aggressive skin cancer, developing in fewer than 2,000 patients in the United States annually. The disease typically presents as a red-violet, painless bump on sun-exposed skin, and definitive treatment requires surgery to remove the cancer. Because recurrence is common, patients are routinely followed for three years after excision.
Should Older Prostate Cancer Patients Jump Off the Active Surveillance Train?
Come December, as I observe my "pros-mitzvah" -- 13 years on active surveillance (AS) for very low-risk prostate cancer -- I feel I'm at a tipping point. Should I stay the course and keep monitoring my lesion -- a single Gleason 6 of less than 1 mm seen back in 2010 and never again in five other biopsies -- with annual or semiannual prostate-specific antigen (PSA) blood tests? Or should I hop off the AS train? Should I make a symbolic move with a PSA jailbreak and end the cancer search? Michael Leapman, MD, MHS, clinical lead in prostate cancer at Yale Cancer Center in New Haven, Connecticut, said: "There's no script for what to do 10-plus years without reclassification [of the Gleason score]."Source: MedPage Today
Bulldog Debates Recap
Yale Urology brought together members of its expert faculty and renowned guest speakers for a carefully crafted CME curriculum at the Yale Club in New York City. The "bulldog debate" format included five distinct sections, focusing on the latest in endourology, FPMRS, prostate cancer, reproductive and sexual medicine, and bladder cancer.
Dr. Petrylak Reviews Results From KEYNOTE-921 in mCRPC
Daniel P. Petrylak, MD, discusses background and findings from the phase 3 KEYNOTE-921 study of pembrolizumab plus docetaxel vs placebo plus docetaxel in patients with metastatic castration-resistant prostate cancer who had received prior next-generation hormonal agent therapy.Source: Targeted Oncology
Sacituzumab Govitecan Continues to Show Efficacy in Pretreated mUC
Treatment with sacituzumab govitecan-hziy (Trodelvy) showed notable efficacy and a manageable safety profile for patients with advanced or unresectable or metastatic urothelial carcinoma (mUC) who had progressed after prior platinum-based combination chemotherapy and checkpoint inhibitors (CPIs), according to promising data shown in the primary analysis of TROPHY-U-01 (NCT03547973) cohort.Source: Targeted Oncology